Cytek Biosciences [CTKB] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Cytek Biosciences
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Cytek Biosciences wins in 5 metrics, Abbott Laboratories wins in 12 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Cytek Biosciences | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 374.50 | 16.43 | Abbott Laboratories |
| Price-to-Book Ratio | 1.31 | 4.51 | Cytek Biosciences |
| Debt-to-Equity Ratio | 3.95 | 26.50 | Cytek Biosciences |
| PEG Ratio | 64.83 | 25.37 | Abbott Laboratories |
| EV/EBITDA | -11.27 | 20.46 | Cytek Biosciences |
| Profit Margin (TTM) | -3.27% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -23.30% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | -1.67% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -3.77% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $21.65M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -21.26% | 21.53% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 2.51 | 5.29 | Cytek Biosciences |
| Enterprise Value | $247.79M | $234.33B | Abbott Laboratories |
| EV/Revenue Ratio | 1.26 | 5.44 | Cytek Biosciences |
| Gross Profit Margin (TTM) | 48.62% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $2 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-0.09 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | N/A | 0.71 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Cytek Biosciences vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Cytek Biosciences | -1.95% | 14.17% | 20.88% | 10.19% | -23.03% | -37.44% |
| Abbott Laboratories | 1.69% | 4.65% | -1.23% | -1.41% | 2.32% | 16.41% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Cytek Biosciences | -21.26% | -72.42% | -78.09% | -78.09% | -78.09% | -78.09% |
| Abbott Laboratories | 21.53% | 18.51% | 32.13% | 163.03% | 450.04% | 491.67% |
Performance & Financial Health Analysis: Cytek Biosciences vs Abbott Laboratories
| Metric | CTKB | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $492.70M | $227.88B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 1,272,570 | 5,718,390 |
| 90 Day Avg. Volume | 1,073,943 | 7,295,300 |
| Last Close | $4.03 | $134.29 |
| 52 Week Range | $2.37 - $7.63 | $107.11 - $141.23 |
| % from 52W High | -47.18% | -4.91% |
| All-Time High | $28.70 (Sep 13, 2021) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -85.96% | -5.83% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.07% |
| Quarterly Earnings Growth | -0.08% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.03% | 0.32% |
| Operating Margin (TTM) | -0.23% | 0.20% |
| Return on Equity (TTM) | -0.02% | 0.31% |
| Debt to Equity (MRQ) | 3.95 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.97 | $29.05 |
| Cash per Share (MRQ) | $2.06 | $4.18 |
| Operating Cash Flow (TTM) | $15.20M | $9.04B |
| Levered Free Cash Flow (TTM) | $26.66M | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Cytek Biosciences vs Abbott Laboratories
| Metric | CTKB | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 374.50 | 16.43 |
| Forward P/E | 64.83 | 25.37 |
| PEG Ratio | 64.83 | 25.37 |
| Price to Sales (TTM) | 2.51 | 5.29 |
| Price to Book (MRQ) | 1.31 | 4.51 |
| Market Capitalization | ||
| Market Capitalization | $492.70M | $227.88B |
| Enterprise Value | $247.79M | $234.33B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.26 | 5.44 |
| Enterprise to EBITDA | -11.27 | 20.46 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.71 |
| Book Value per Share (MRQ) | $2.97 | $29.05 |
Financial Statements Comparison: Cytek Biosciences vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | CTKB | ABT |
|---|---|---|
| Revenue/Sales | $41.46M | $10.36B |
| Cost of Goods Sold | $21.30M | $4.47B |
| Gross Profit | $20.16M | $5.89B |
| Research & Development | $9.73M | $716.00M |
| Operating Income (EBIT) | $-14.98M | $1.69B |
| EBITDA | $-8.09M | $2.66B |
| Pre-Tax Income | $-11.27M | $1.78B |
| Income Tax | $136,000 | $453.00M |
| Net Income (Profit) | $-11.40M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | CTKB | ABT |
|---|---|---|
| Cash & Equivalents | $95.30M | $6.53B |
| Total Current Assets | $380.50M | $23.15B |
| Total Current Liabilities | $67.69M | $13.00B |
| Long-Term Debt | $8.37M | $12.74B |
| Total Shareholders Equity | $379.62M | $49.06B |
| Retained Earnings | $-46.60M | $47.72B |
| Property, Plant & Equipment | $21.62M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | CTKB | ABT |
|---|---|---|
| Operating Cash Flow | $3.22M | $1.42B |
| Capital Expenditures | $-816,000 | $-484.00M |
| Free Cash Flow | $-976,000 | $933.00M |
| Debt Repayment | $-1.52M | $-1.00B |
| Common Stock Repurchase | $-10.63M | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | CTKB | ABT |
|---|---|---|
| Shares Short | 5.65M | 19.06M |
| Short Ratio | 4.54 | 3.12 |
| Short % of Float | 0.06% | 0.01% |
| Average Daily Volume (10 Day) | 1,272,570 | 5,718,390 |
| Average Daily Volume (90 Day) | 1,073,943 | 7,295,300 |
| Shares Outstanding | 129.21M | 1.73B |
| Float Shares | 108.71M | 1.73B |
| % Held by Insiders | 0.09% | 0.01% |
| % Held by Institutions | 0.60% | 0.81% |
Dividend Analysis & Yield Comparison: Cytek Biosciences vs Abbott Laboratories
| Metric | CTKB | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |